FGFR1 and hepatocellular carcinoma: In orthotopic mouse models of HCC, lenvatinib and FGFR-1/2/3/4 inhibitors, which commonly inhibit FGFR signaling, alter the TIME to an immune hot state by downregulating metabolic pathway signaling.